Skip to content
Screener

Ashland ASH Life Sciences — Depreciation

Other segment segments

Specialty Additives
$13M-61.8%
Personal Care And Household
$7M0.0%
Intermediates And Solvents
$1M-66.7%
Unallocated And Other
$1M

Similar metrics at other companies

Revvity logo
RVTYLife Sciences — Depreciation
$9.91M+37.9%
PTC Therapeutics logo
PTCTLife Science — Depreciation
$3.81M+10.1%
Agilent Technologies logo
ALife Sciences and Diagnostics Markets — Depreciation
$26M+8.3%
Sunbelt Rentals Holdings logo
SUNBSpecialty — Depreciation
$141M+6.0%
Sunbelt Rentals Holdings logo
SUNBU.K. — Depreciation
$43M+2.4%
Cato Corporation logo
CATOCredit — Depreciation
$0

Other financials

Income statement

See full
Revenue$497.0M+7.3%
Gross profit$170.0M+28.8%
Operating income$43.0M+106%
Net income$16.0M+102%
EPS (diluted)$0.35+102%

Balance sheet

See full
Cash & equivalents$440.0M+113%
Total debt$1.5B-0.6%
Total equity$1.9B-1.0%
Total assets$4.6B-0.9%

Cash flow

See full
Operating cash flow$120.0M+4.3%
CapEx$20.0M0.0%
Free cash flow$100.0M+5.3%

Valuation

See full
Market cap$3.32B+40.6%
Enterprise value$4.35B+19.7%
P/E165.9×
P/S1.8×+0.5×

Profitability

See full
Gross margin31.5%+1.4pp
Operating margin4.1%
Net margin1.1%+0.5pp
FCF margin13.6%+9.7pp

Returns & leverage

See full
Return on equity1.1%+0.5pp
Debt / equity0.8×0.0×
Current ratio+0.4×

Where this comes from

Reported directly by Ashland in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The source filing: Ashland’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 5:17 PM EDT
Fiscal quarter
Q3 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-324226
(In millions - unaudited)Three months ended / June 30 / 2026Three months ended / June 30 / 2025Nine months ended / June 30 / 2026Nine months ended / June 30 / 2025
Other net periodic benefit (income) loss(5)1(3)4
Income (loss) from continuing operations before income taxes$56$(704)$60$(874)
Depreciation expense
Life Sciences(d)$10$17$29$48
Personal Care(e)772123
Specialty Additives(e)13344060
Intermediates1349
Total operating segments316194140

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Ashland's life sciences — depreciation?
Ashland (ASH) reported life sciences — depreciation of $10M in Q2 2026.
How has Ashland's life sciences — depreciation changed year-over-year?
Ashland's life sciences — depreciation decreased by 41.2% year-over-year, from $17M to $10M.
What is the long-term trend for Ashland's life sciences — depreciation?
Over 4 years (2021 to 2025), Ashland's life sciences — depreciation has grown at a 12.2% compound annual growth rate (CAGR), from $36M to $57M.
What does life sciences — depreciation mean?
This represents the systematic allocation of the cost of tangible assets over their useful lives within the Life Sciences segment. It reflects the wear and tear or obsolescence of manufacturing facilities and equipment used to produce specialty materials. Monitoring this helps investors understand the capital intensity and the ongoing reinvestment requirements of the segment.

Ask your AI about Ashland's life sciences — depreciation.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude